Q2FY22 Quarterly Result Announced for Indoco Remedies Ltd.
Highlights: Indoco’s EBIDTA jumps 43 % in Q2FY22 During the second quarter of FY 2021-22, revenues of Indoco Remedies grew by 15.6 % at Rs. 372.6 crores, as against Rs. 322.5 crores, same quarter last year. EBIDTA to net sales for the quarter is 23.2% at Rs. 86.3 crores, compared to 18.7% at Rs. 60.2 crores, same quarter last year. For the quarter, the Profit After Tax to net sales is 11.2 % at Rs. 41.6 crores, compared to 7.8 % at Rs. 25.1 crores, same quarter last year. For the first half of the year FY 2021-22, the revenues grew by 27.9 % at Rs. 753.8 crores, as against Rs. 589.3 crores, same period last year. EBIDTA to net sales for the period is 22.9 % at Rs. 173.1 crores, compared to 18.5% at Rs. 109.0 crores, same period last year. For the period, the Profit After Tax to net sales is 10.8% at Rs. 81.2 crores, compared to 7.2% at Rs. 42.3 crores, same period last year. Commenting on the second quarter FY22 results, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “Robust sales growth coupled with efficiency in operations has enabled us to deliver excellent financials this quarter”. Result PDF02-11-2021
